CD274 and colitis: A recent study reported synergistic toxicities (pneumonitis and colitis) were found only in patients treated with sequential PD-(L)1 blockade and an EGFR (epidermal growth factor receptor) tyrosine kinase inhibitor, osimertinib [37].